Latest Commercialisation Strategy News

Epiminder Limited has achieved a major milestone with the first US implant of its Minder System at the University of Pennsylvania, kicking off a pivotal trial that could redefine epilepsy monitoring.

Vitrafy Life Sciences has secured a 12-month exclusive partnership with global animal reproduction leader IMV Technologies to co-develop and commercialise next-generation cryopreservation solutions for farm animals and aquaculture.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

UC San Diego Health has begun clinical use of 4DMedical’s CT – VQ™, marking the fourth leading US academic medical centre to adopt this innovative lung imaging technology since FDA clearance. This milestone underscores 4DMedical’s rapid commercial traction and growing influence in respiratory diagnostics.

4DMedical secures Cleveland Clinic as the third major US academic medical centre to adopt its CT – VQ™ respiratory imaging technology, marking rapid commercial traction post-FDA clearance.

Avecho Biotechnology is close to completing recruitment for the interim analysis cohort of its pivotal Phase III trial testing a CBD capsule for insomnia, with results expected in the first half of 2026.

Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

Aurora Labs has secured its first $250,000 order for AU4 propulsion engines from Sovereign Propulsion Systems, marking a key step in its commercialisation strategy targeting unmanned aerial vehicles and defence markets.

Orthocell has achieved its first commercial sales of Remplir™ in Hong Kong, marking a pivotal step in its Asian growth strategy and expanding its footprint across key global markets.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

I Synergy Group’s subsidiary has inked four separate 12-month leases for its AI computing hardware and software, marking a strategic push into recurring revenue streams.